Hodgkin Lymphoma

Recognizing the risk for first-degree relatives may potentially increase awareness of early symptoms among family members of HL patients, leading to earlier diagnosis and better outcomes. Conversely, understanding that the hereditary risk, though higher than in the general population, remains relatively low may provide reassurance for affected families.

P=N/A, N=0, Withdrawn, Centre Hospitalier Universitaire, Amiens | N=750 --> 0 | Unknown status --> Withdrawn

Despite this scientific and clinical progress, the high cost of developing CAR T cells through the traditional biopharma pathway is limiting late-stage clinical development, necessitating the creation of new business models to commercialize CAR T cells for these small markets. CAR T cells hold great promise for improving outcomes for pediatric patients with cancer, but substantial additional research and clinical development is needed if this promise is to be realized for children afflicted with cancer.

In clinical samples from patients with BC, serum levels of miR‑155 align with both tumor miR‑155 levels and the immune status of the tumor. The present review emphasizes the importance of understanding the dynamics between TILs and miRNAs to identify new prognostic and predictive biomarkers, proposing a more integrated and personalized approach in the management of BC..

In vitro treatment of primary HRS cells with BCL2 inhibitor, venetoclax, augmented induction of apoptosis in HRS cells and other cells of the HL immune microenvironment. These findings support further study of targeting apoptosis resistance as a potential approach to eliminate malignant HRS cells and dismantle inflammatory lesion formation in pediatric HL.

Whole-exome sequencing of the four family members revealed a novel pathogenic missense mutation in the CD38 gene (c.418 C > T, p.Arg140Trp), which was found to be inherited in an autosomal recessive manner. Herein, we identified a putative pathogenic genetic variant that may be associated with HL, which will contribute to improve the understanding of the genetic molecular mechanisms underlying the disease.

P1, N=20, Recruiting, AIDS Malignancy Consortium | Trial completion date: Jan 2027 --> Jan 2029 | Trial primary completion date: Jan 2026 --> Jan 2028

This case highlights the diagnostic challenge of distinguishing rare lymphomas from common infections in tuberculosis-endemic regions and underscores the necessity of early tissue diagnosis with immunophenotyping when faced with unexplained large pleuro-pericardial effusions. Prompt recognition is crucial because T-LBL requires intensive ALL-type therapy, which significantly improves survival compared with conventional lymphoma regimens.

P1, N=22, Completed, Seagen, a wholly owned subsidiary of Pfizer | Active, not recruiting --> Completed

So, it seems possible to characterize localized single cells in tissues using hybridization and sequencing technologies to provide further information of cell-cell interactions and the resulting molecular changes by bioinformatics.These developments open new perspectives for personalised medicine and could help to better predict the success of innovative cell therapies. This article was created to accompany the 62nd IAP Symposium, "Lymph Nodes and Lymphoma Pathology-The Essentials."

Treatment with oral etretinate and narrowband ultraviolet B phototherapy resulted in improvement of the MF lesions, and no recurrence of the erythematous papules has been observed. As LyP may morphologically resemble cutaneous involvement of HL or MF with LCT, comprehensive evaluation, including clinical course, imaging findings, and immunophenotypic analysis, is essential for accurate diagnosis.

P=N/A, N=40, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting